Ingevity Inkomsten in het verleden
Verleden criteriumcontroles 0/6
De winst van Ingevity is gedaald met een gemiddeld jaarlijks percentage van -59%, terwijl de winst van de Chemicals -industrie jaarlijks daalde met 3.8%. De inkomsten zijn daalde met een gemiddeld percentage van 2.6% per jaar.
Belangrijke informatie
-58.96%
Groei van de winst
-58.61%
Groei van de winst per aandeel
| Chemicals Groei van de industrie | 12.93% |
| Inkomstengroei | -2.57% |
| Rendement op eigen vermogen | -401.03% |
| Nettomarge | -13.25% |
| Laatste winstupdate | 31 Mar 2026 |
Recente prestatie-updates uit het verleden
Recent updates
Analyse-update • Apr 28
NGVT: Future P/E Will Reflect Margin Resilience And Impairment Charge Impact
Analysts have increased their price target for Ingevity to $80.50 from $79.25, citing updated assumptions on long term revenue growth, profit margin resilience, and future P/E levels reflected in recent research, including the Wells Fargo target increase. Analyst Commentary Recent research behind the new US$80.50 price target focuses on refreshed assumptions for long term revenue trends, margin resilience, and the P/E level that investors may be willing to ascribe to Ingevity over time.Analyse-update • Apr 11
NGVT: Future P/E Will Depend On Margin Execution And Impairment Fallout
Analysts have raised their price target on Ingevity by $5 to $79.25, citing updated assumptions regarding discount rates, long-term revenue growth, profit margins, and future P/E expectations. Analyst Commentary Analysts raising the price target to $79.25 are updating their models to reflect changes in discount rates, long term revenue assumptions, profit margins, and future P/E expectations.Analyse-update • Mar 28
NGVT: Higher P/E Will Rely On Future Margin Delivery
Analysts have lifted their price target on Ingevity by $5 to $79.25, citing updated assumptions on discount rates, long term revenue growth, profit margins, and future P/E, which support a slightly higher valuation outlook. Analyst Commentary Bullish Takeaways Bullish analysts see the higher price target as consistent with updated assumptions on discount rates and long term revenue growth, which they believe better reflect the company’s current risk profile and earnings potential.Analyse-update • Mar 13
NGVT: Higher P/E Outlook Will Depend On Margin Execution
Analysts have raised their price target on Ingevity by $8.50 to $79.25, citing updated views on revenue growth, profit margins, and an expected higher future P/E multiple. Analyst Commentary Recent Street research has focused on how Ingevity might justify a higher valuation, with specific attention on revenue trends, profitability, and the potential for the shares to support a richer P/E multiple over time.Analyse-update • Feb 24
NGVT: Updated P/E Assumptions And Buybacks Will Shape Balanced Outlook
Analysts have raised their price target on Ingevity by $5 to $70.75, citing updated assumptions around discount rates and future P/E as the main factors behind this revised view. Analyst Commentary Analysts framing the new US$70.75 price target are focusing less on short term headlines and more on what updated discount rate and P/E assumptions imply for Ingevity's risk profile and execution needs.Analyse-update • Feb 09
NGVT: Share Repurchases And Battery Materials License Will Guide Balanced Outlook
Analysts have raised their price target on Ingevity from US$69.50 to US$70.75, citing updated assumptions around discount rates, revenue trends, profit margins and future P/E expectations. Analyst Commentary Analysts who support the higher price target describe it as a fine tuning of their models rather than a wholesale rethink.Analyse-update • Jan 26
NGVT: Buybacks And Battery Materials License Will Shape Balanced Outlook
Analysts have maintained their fair value estimate for Ingevity at US$69.50, with only minor adjustments to inputs such as the discount rate and long-term P/E assumptions. These changes reflect updated modeling rather than a change in conviction.Analyse-update • Jan 10
NGVT: Battery Additives And Buybacks Will Shape Balanced Long-Term Outlook
Analysts have adjusted their price target on Ingevity to US$69.50. This reflects updated views on the discount rate, revenue outlook, profit margins and future P/E assumptions.Analyse-update • Dec 25
NGVT: Future Battery Materials Role Will Drive Long-Term Upside Despite Margin Reset
Analysts have modestly raised their price target on Ingevity by about $1.25 to approximately $69.50. They cite a lower perceived discount rate and an improving revenue trajectory, which more than offset concerns about a structurally lower profit margin and a higher future valuation multiple.Analyse-update • Dec 10
NGVT: Future Battery Materials Role Will Drive Stronger Long Term Upside Potential
Analysts have nudged their price target on Ingevity higher from $65.25 to $68.25, citing a modestly richer future earnings multiple that more than offsets slightly softer revenue growth and margin assumptions. What's in the News Ingevity announced that Executive Vice President and Chief Financial Officer Mary Dean Hall will transition from her role effective May 1, 2026, and remain in an advisory capacity for one year, as part of a planned leadership change.Analyse-artikel • Sep 30
Is There Now An Opportunity In Ingevity Corporation (NYSE:NGVT)?
While Ingevity Corporation ( NYSE:NGVT ) might not have the largest market cap around , it received a lot of attention...Analyse-artikel • Sep 06
Does Ingevity (NYSE:NGVT) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Sep 05
Ingevity: No Specialty Play, Awaiting External Drivers
Summary Ingevity Corporation's shares look cheap on earnings multiples, but a poor track record and capital allocation mistakes limit my conviction. Recent divestment of low-margin assets slightly improves leverage, but has minimal impact on overall earnings and does not address core issues. Performance materials segment remains highly profitable, suggesting a potential spin-off could unlock value, but no such move is imminent. Despite undemanding valuation, lack of dividends, modest buybacks, and no clear catalyst keep me on the NGVT sidelines for now. Read the full article on Seeking AlphaAnalyse-update • Sep 05
Portfolio Repositioning And Engineered Additives Will Create A Sustainable Future
Consensus analyst price targets for Ingevity have risen to $65.25, reflecting increased confidence in continued earnings and free cash flow growth following a strong Q2 beat and improved operational outlook. Analyst Commentary Q2 earnings beat, demonstrating stronger-than-expected financial performance.Analyse-update • Aug 06
Portfolio Repositioning And Engineered Additives Will Create A Sustainable Future
The upward revision in Ingevity's revenue growth forecasts from 2.6% to 3.7% per annum has outweighed the impact of a higher discount rate, resulting in an increased consensus analyst price target from $54.25 to $57.00. What's in the News Ingevity Corporation maintained its earnings guidance for 2025, expecting sales between $1.25 billion and $1.40 billion.Analyse-artikel • Jun 27
Ingevity Corporation (NYSE:NGVT) Shares Could Be 39% Below Their Intrinsic Value Estimate
Key Insights The projected fair value for Ingevity is US$71.30 based on 2 Stage Free Cash Flow to Equity Ingevity's...Analyse-artikel • May 28
Subdued Growth No Barrier To Ingevity Corporation (NYSE:NGVT) With Shares Advancing 33%
Those holding Ingevity Corporation ( NYSE:NGVT ) shares would be relieved that the share price has rebounded 33% in the...Nieuwe analyse • May 27
Premium Markets Will Secure Long Term Value
Expansion into premium specialty chemicals and advanced materials is increasing margins and positioning for growth as sustainability trends and vehicle electrification accelerate.Analyse-artikel • Apr 05
Why We're Not Concerned Yet About Ingevity Corporation's (NYSE:NGVT) 32% Share Price Plunge
Ingevity Corporation ( NYSE:NGVT ) shares have had a horrible month, losing 32% after a relatively good period...Analyse-artikel • Feb 20
Ingevity (NYSE:NGVT) Has A Somewhat Strained Balance Sheet
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Analyse-artikel • Jan 16
Ingevity Corporation (NYSE:NGVT) Shares Could Be 49% Below Their Intrinsic Value Estimate
Key Insights Ingevity's estimated fair value is US$82.84 based on 2 Stage Free Cash Flow to Equity Ingevity is...Analyse-artikel • Nov 07
What Ingevity Corporation's (NYSE:NGVT) 32% Share Price Gain Is Not Telling You
Ingevity Corporation ( NYSE:NGVT ) shareholders have had their patience rewarded with a 32% share price jump in the...Analyse-artikel • Oct 13
Is Ingevity (NYSE:NGVT) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analyse-artikel • Sep 08
Ingevity Corporation's (NYSE:NGVT) Prospects Need A Boost To Lift Shares
When you see that almost half of the companies in the Chemicals industry in the United States have price-to-sales...Seeking Alpha • Aug 27
Ingevity: The Risk-Reward Ratio Is Still Unfavorable
Summary Ingevity, once considered a growth story, turned out to be a classic example of market cycles. While Road Technology and Performance Materials performed reasonably well in the first half of 2024, the Industrial Specialties segment dragged down revenue and net income. Given the company's significant debt burden, risk-averse investors should seek safer options within the chemical industry. Read the full article on Seeking AlphaAnalyse-artikel • Aug 03
Ingevity Corporation Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
There's been a notable change in appetite for Ingevity Corporation ( NYSE:NGVT ) shares in the week since its quarterly...Analyse-artikel • Jul 13
Ingevity (NYSE:NGVT) Use Of Debt Could Be Considered Risky
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analyse-artikel • Jun 14
Should You Investigate Ingevity Corporation (NYSE:NGVT) At US$45.90?
Ingevity Corporation ( NYSE:NGVT ), might not be a large cap stock, but it received a lot of attention from a...Analyse-artikel • Apr 18
Are Investors Undervaluing Ingevity Corporation (NYSE:NGVT) By 44%?
Key Insights Ingevity's estimated fair value is US$78.59 based on 2 Stage Free Cash Flow to Equity Current share price...Analyse-artikel • Mar 22
Is Ingevity (NYSE:NGVT) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analyse-artikel • Jan 23
What Is Ingevity Corporation's (NYSE:NGVT) Share Price Doing?
Ingevity Corporation ( NYSE:NGVT ), might not be a large cap stock, but it saw a double-digit share price rise of over...Analyse-artikel • Jan 04
Ingevity Corporation (NYSE:NGVT) Doing What It Can To Lift Shares
With a price-to-earnings (or "P/E") ratio of 12.6x Ingevity Corporation ( NYSE:NGVT ) may be sending bullish signals at...Analyse-artikel • Nov 10
These Analysts Just Made An Incredible Downgrade To Their Ingevity Corporation (NYSE:NGVT) EPS Forecasts
The latest analyst coverage could presage a bad day for Ingevity Corporation ( NYSE:NGVT ), with the analysts making...Opbrengsten en kosten
Opbrengsten en kosten
Hoe Ingevity geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 31 Mar 26 | 1,178 | -156 | 170 | 28 |
| 31 Dec 25 | 1,168 | -150 | 171 | 28 |
| 30 Sep 25 | 1,382 | -361 | 177 | 31 |
| 30 Jun 25 | 1,383 | -354 | 171 | 30 |
| 31 Mar 25 | 1,350 | -354 | 163 | 29 |
| 31 Dec 24 | 1,200 | -121 | 158 | 25 |
| 30 Sep 24 | 1,309 | -258 | 163 | 25 |
| 30 Jun 24 | 1,421 | -280 | 165 | 27 |
| 31 Mar 24 | 1,640 | -112 | 183 | 30 |
| 31 Dec 23 | 1,216 | 106 | 162 | 25 |
| 30 Sep 23 | 1,704 | 127 | 196 | 32 |
| 30 Jun 23 | 1,740 | 177 | 210 | 32 |
| 31 Mar 23 | 1,678 | 202 | 207 | 32 |
| 31 Dec 22 | 1,668 | 212 | 198 | 30 |
| 30 Sep 22 | 1,621 | 225 | 191 | 30 |
| 30 Jun 22 | 1,516 | 146 | 181 | 29 |
| 31 Mar 22 | 1,454 | 130 | 179 | 27 |
| 31 Dec 21 | 1,392 | 118 | 179 | 26 |
| 30 Sep 21 | 1,381 | 135 | 169 | 25 |
| 30 Jun 21 | 1,336 | 209 | 160 | 24 |
| 31 Mar 21 | 1,248 | 185 | 151 | 23 |
| 31 Dec 20 | 1,216 | 181 | 150 | 23 |
| 30 Sep 20 | 1,194 | 180 | 153 | 22 |
| 30 Jun 20 | 1,222 | 170 | 159 | 21 |
| 31 Mar 20 | 1,304 | 206 | 163 | 21 |
| 31 Dec 19 | 1,293 | 184 | 163 | 20 |
| 30 Sep 19 | 1,268 | 182 | 158 | 20 |
| 30 Jun 19 | 1,219 | 171 | 152 | 21 |
| 31 Mar 19 | 1,175 | 161 | 145 | 22 |
| 31 Dec 18 | 1,134 | 169 | 133 | 22 |
| 30 Sep 18 | 1,085 | 169 | 125 | 22 |
| 30 Jun 18 | 1,037 | 153 | 116 | 21 |
| 31 Mar 18 | 989 | 138 | 107 | 20 |
| 31 Dec 17 | 972 | 127 | 107 | 20 |
| 30 Sep 17 | 954 | 94 | 104 | 19 |
| 30 Jun 17 | 942 | 53 | 103 | 18 |
| 31 Mar 17 | 927 | 45 | 100 | 18 |
| 31 Dec 16 | 908 | 35 | 96 | 18 |
| 30 Sep 16 | 898 | 34 | 93 | 13 |
| 30 Jun 16 | 902 | 64 | 95 | 9 |
| 31 Mar 16 | 919 | 66 | 105 | 5 |
| 31 Dec 15 | 958 | 80 | 93 | 17 |
| 30 Sep 15 | 999 | 99 | 107 | 8 |
| 30 Jun 15 | 1,025 | 115 | 108 | 8 |
Kwaliteitswinsten: NGVT is momenteel verliesgevend.
Groeiende winstmarge: NGVT is momenteel verliesgevend.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: NGVT is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 59% per jaar.
Versnelling van de groei: Het is niet mogelijk om de winstgroei van NGVT over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.
Winst versus industrie: NGVT is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Chemicals industrie ( 0.7% ).
Rendement op eigen vermogen
Hoge ROE: NGVT heeft een negatief Return on Equity ( -401.03% ), omdat het momenteel verliesgevend is.
Rendement op activa
Rendement op geïnvesteerd vermogen
Ontdek sterk presterende bedrijven uit het verleden
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/11 18:16 |
| Aandelenkoers aan het einde van de dag | 2026/05/11 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Ingevity Corporation wordt gevolgd door 8 analisten. 4 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Paretosh Misra | Berenberg |
| John McNulty | BMO Capital Markets Equity Research |
| Jonathan Tanwanteng | CJS Securities, Inc. |